Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129258 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT01129258 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 110 participants.
The verdict
NCT01129258, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-04991532 following multiple (14 days) escalating oral doses in patient wtih type 2 diabetes.
Interventions
- DRUG Placebo
- DRUG PF-04991532
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129258
The ClinicalTrials.gov registry entry for NCT01129258 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01129258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129258 about?
NCT01129258 is a clinical study titled "Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes". The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-04991532 following multiple (14 days) escalating oral doses in patient wtih type 2 diabetes.
What is the current status of trial NCT01129258?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2010-06. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01129258?
The interventions under investigation include: Placebo (DRUG), PF-04991532 (DRUG).
Who is sponsoring clinical trial NCT01129258?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.